Drug Trial Radar · NCT06228053
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
53
Planned (sponsor's estimate)
Start
Nov 18, 2024
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Syntrix Biosystems, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
SX-682Drug
Specified dose twice daily
EnzalutamideDrug
Specified dose once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical BenefitTime frame: Ten 21-day treatment cycles
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Not yet recruiting
Duke University
Durham, North Carolina · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.